{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:31:46Z","timestamp":1791477106595,"version":"4.3.4"},"reference-count":34,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014756","name":"Hexal AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1080\/14712598.2024.2428299","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T11:08:30Z","timestamp":1731668910000},"page":"1375-1385","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5375-9717","authenticated-orcid":false,"given":"Lena","family":"Lemke","sequence":"first","affiliation":[{"name":"Hexal AG (A Sandoz company), Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Blauvelt Consulting, LLC, Lake Oswego, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Br\u00fcckmann","sequence":"additional","affiliation":[{"name":"Hexal AG (A Sandoz company), Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8758-0890","authenticated-orcid":false,"given":"Hillel P.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Sandoz Inc, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8771-6085","authenticated-orcid":false,"given":"Jamie","family":"Fan","sequence":"additional","affiliation":[{"name":"Sandoz Inc, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Guerrieri","sequence":"additional","affiliation":[{"name":"Hexal AG (A Sandoz company), Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Horvat","sequence":"additional","affiliation":[{"name":"Lek d.d. (A Sandoz company), Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Poetzl","sequence":"additional","affiliation":[{"name":"Hexal AG (A Sandoz company), Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Torella","sequence":"additional","affiliation":[{"name":"Sandoz, Kundl, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Hexal AG (A Sandoz company), Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5262-9922","authenticated-orcid":false,"given":"Oliver","family":"von Richter","sequence":"additional","affiliation":[{"name":"Hexal AG (A Sandoz company), Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2022.88809"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26438"},{"key":"e_1_3_9_6_1","unstructured":"U.S. Food and Drug Administration. Review and approval. 2022 [cited 2024 Mar 26]. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/review-and-approval"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00538-6"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111517"},{"key":"e_1_3_9_9_1","unstructured":"European Medicines Agency. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2023 [cited 2024 Mar 26]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf"},{"issue":"1","key":"e_1_3_9_10_1","first-page":"5","article-title":"FDA\u2019s Gottlieb aims to end biosimilars groundhog day","volume":"28","author":"Kirkner RM","year":"2019","unstructured":"Kirkner RM. FDA\u2019s Gottlieb aims to end biosimilars groundhog day. Manag Care. 2019;28(1):5\u20136.","journal-title":"Manag Care"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1238454"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1954"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00446-7"},{"key":"e_1_3_9_14_1","unstructured":"U.S. Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product guidance for industry. 2019 [cited 2024 Mar 26]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-guidance-industry."},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16890"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5069678"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2017-0185"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-022-00728-8"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2023-0152"},{"key":"e_1_3_9_20_1","volume-title":"Nonparametrics: statistical methods based on ranks","author":"Lehmann E","year":"2006","unstructured":"Lehmann E. Nonparametrics: statistical methods based on ranks. 1 ed. New York (NY): Springer; 2006.","edition":"1"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.09.020"},{"key":"e_1_3_9_22_1","unstructured":"U.S. Food and Drug Administration. Immunogenicity testing of therapeutic protein products \u2014 developing and validating assays for anti-drug antibody detection. 2019 [cited 2024 Apr 10]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00846-x"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00708-w"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00600-x"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00161-3"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.278"},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3033"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01601-2"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-219951"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00655-4"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1836"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00546-6"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01371-8"},{"key":"e_1_3_9_35_1","unstructured":"IQVIA. Biosimilars in the United States 2023-2027: competition savings and sustainability. 2023 [cited 2024 Mar 26]. Available from: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/biosimilars-in-the-united-states-2023-2027"},{"key":"e_1_3_9_36_1","unstructured":"U.S. Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: update guidance for industry. 2024 [cited 2024 Oct 9]. Available from: https:\/\/www.fda.gov\/media\/179456\/download"}],"updated-by":[{"DOI":"10.1080\/1750743x.2026.2624291","type":"addendum","label":"Addendum","source":"publisher","updated":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000}}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2428299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T16:42:20Z","timestamp":1733330540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2428299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1080\/14712598.2024.2428299"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2428299","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}